Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06557291
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-13
Brief Title:
Relapse-Free Survival With Adjuvant DabrafenibTrametinib Therapy in Patients With BRAF V600-mutated Stage IIIIV Melanoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Relapse-Free Survival With Adjuvant DabrafenibTrametinib Therapy After Relapse on Adjuvant Checkpoint Inhibitor Therapy and Subsequent Surgical Resection in Patients With BRAF V600-mutated Stage IIIIV Melanoma
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a retrospective chart review study of all proto-oncogene B-Raf BRAF V600-mutated patients who received adjuvant checkpoint inhibitor CPI therapy relapsed locoregionally or distantly and were again resected to no evidence of disease NED and treated with adjuvant dabrafenib and trametinib dabtram combination therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: